Mrpl50 integrates glucolipotoxicity with hypoxia-inducible factor 1 alpha signaling to drive diabetic kidney disease

Area of Science:

• Nephrology
• Metabolic Disorders
• Molecular Biology

Background:

• Diabetic kidney disease (DKD) is a major complication of diabetes, leading to renal failure and cardiovascular complications.
• Glucolipotoxicity is a key driver of DKD, causing renal tubular injury through incompletely understood mechanisms.

Purpose of the Study:

• To identify novel mediators of glucolipotoxicity in DKD.
• To elucidate the role of Mrpl50 in DKD pathogenesis and its underlying molecular mechanisms.

Main Methods:

• Analysis of Mrpl50 expression in DKD models and patient samples.
• Functional studies using Mrpl50-deficient and overexpressing renal tubular cells.
• Investigation of the HIF-1α pathway in response to Mrpl50 modulation.

Main Results:

• Mrpl50 expression is upregulated under metabolic stress and correlates with DKD progression.
• Mrpl50 deficiency attenuated glucolipotoxic damage in renal tubular cells.
• Mrpl50 overexpression amplified inflammatory responses via the HIF-1α pathway.

Conclusions:

• Mrpl50 acts as a critical mediator of glucolipotoxic damage and renal inflammation in DKD.
• Mrpl50 functions as a molecular sensor distinguishing true hypoxia from pseudo-hypoxia, regulating the HIF-1α response.
• Targeting Mrpl50 may offer a novel therapeutic strategy for managing DKD progression.